TrialThe Journal of infectious diseases2025

HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines.

Gregory J Wilson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.